Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Molecular MRD detection in AML

Peter Valk • 14 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia

In this video Peter Valk, PhD, from the Erasmus University Medical Center, Rotterdam, Netherlands, discusses precision medicine in acute myeloid leukemia (AML), namely biomarkers for early detection and molecular measurable residual disease detection. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Peter Valk

1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022
3:22
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
Peter Valk • 29 Sep 2022
1:49
The prognostic value of FLT3-ITD residual disease in AML
Peter Valk • 29 Sep 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals